Thus, all 13 affected individuals with a clinical diagnosis of Gillespie syndrome that were available to us for study were found to have ultra-rare protein-altering variations affecting only three residues in ITPR1, with at least ten of these mutations having occurred de novo. This evidence concerns the gene ITPR1 and aniridia-cerebellar ataxia-intellectual disability syndrome.